Gallant: Valuation, Funding & Investors
Gallant is a pioneering company in veterinary regenerative medicine, focused on developing ready-to-use stem cell therapies for pets. The company is advancing its first stem cell therapy through conditional FDA approval, leveraging expertise from leaders in human stem cell therapies to enhance its offerings in the animal health industry.
Leadership & Board
- Current Number of Employees
- 76
- Current LinkedIn Followers
- 4,221
Latest Estimated Valuation
- Total Amount Raised
- $18M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $18M
- Latest Funding Round
- Series B
Company Momentum Positive
Gallant LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Gallant had 76 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Gallant had 4,221 followers as of October 26, 2026. The number of followers increased by 14 (0.33%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jun 30, 2025 | Series B | $18.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Bold Capital | Series B |
| Digitalis Ventures | Series B |
| NovaQuest | Series B |
| Hill Creek Partners | Series B |
Similar Companies
A snapshot of private companies similar to Gallant, helping you discover and navigate related company profiles.
Related News and Analysis
